Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 58 Lymphoma, Large B-Cell, Diffuse 25 Lymphoma, Follicular 23 Lymphoma 18 Leukemia, Lymphocytic, Chronic, B-Cell 17 Recurrence 16 Lymphoma, Non-Hodgkin 14 Lymphoma, Mantle-Cell 14 Lymphoma, B-Cell, Marginal Zone 12 Lymphoma, B-Cell 10 Neoplasms, Plasma Cell 9 Waldenstrom Macroglobulinemia 6 Hodgkin Disease 6 Neoplasms 5 Leukemia, Myeloid, Acute 5 Burkitt Lymphoma 5 Lymphoma, T-Cell 4 Prostatic Neoplasms 3 Ovarian Neoplasms 3 Myelodysplastic Syndromes 3 Lymphoma, T-Cell, Peripheral 3 Lymphoma, Large-Cell, Anaplastic 3 Leukemia 3 Hematologic Neoplasms 3 Sezary Syndrome 2 Paraproteinemias 2 Pancreatic Neoplasms 2 Neoplasm Metastasis 2 Mycosis Fungoides 2 Lymphoma, Large-Cell, Immunoblastic 2

Interventions

pembrolizumab 2 Paclitaxel 2 Carboplatin 2 poly(I).poly(c12,U) 1 liposomal doxorubicin 1 Lenalidomide 1 Interferon alpha-2 1 Gemcitabine 1 Cisplatin 1 Bevacizumab 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Ovarian Cancer Recurrent × Lenalidomide × Clear all

NCT01111903 2016-03-17

REV

ARCAGY/ GINECO GROUP

Phase 1/2 Completed

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡